Hepatic Dysfunction and Jaundice in Patients Receiving Triacetyloleandomycin

Abstract

TRIACETYLOLEANDOMYCIN (TriA), a drug that has been introduced for the treatment of infection caused by staphylococcic and other gram-positive organisms, has been widely used, minimal toxicity being reported. Several isolated cases of jaundice in children receiving the drug have been observed.1 , 2 Robinson,3 however, has recently reported that in 5 of 48 patients who received TriA for fourteen days or longer elevated serum glutamic pyruvic transaminase values developed. These observations seem at variance with the previous reports4 , 5 of lack of side effects in patients receiving the drug for periods of sixty days or more.The present study was undertaken in the . . .